8-K current report · filed Aug 12, 2026

Liquidia Corp (LQDA) 8-K Current Report: August 12, 2026

Item 2.02Item 8.01Item EX-99.1Item EX-99.2LQDA overview

Short answer

Liquidia Corp (LQDA) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Liquidia announced financial results for the quarter ended June 30, 2026.

Liquidia Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Liquidia announced financial results for the quarter ended June 30, 2026
  • Corporate update included alongside the quarterly results
  • Detailed figures and management commentary are in Exhibit 99.1, the accompanying press release

Item 8.01 · Other Events

  • Updated corporate presentation for healthcare conferences, analysts, stockholders, and other audiences
  • Exhibit 99.2 contains the investor-facing presentation and may outline current strategy, pipeline, or business priorities

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 product sales reached $170.4M, up 31% sequentially, confirming rapid YUTREPIA commercial adoption
  • Net income $74.7M and adjusted EBITDA $96.3M marked the fourth consecutive quarter of improving profitability
  • Cash and equivalents rose to $284.2M from $190.7M at December 31, 2025, strengthening funding for commercialization and clinical development
  • YUTREPIA generated approximately 5,900 prescriptions and treated more than 5,000 patients since June 2025
  • L606 Re-Spire pivotal study enrollment and 10 clinical studies expand potential indications, but ongoing United Therapeutics litigation remains a commercialization risk

Item EX-99.2 · Exhibit EX-99.2

  • Q2 2026 product sales $170.4M, up 31% sequentially, confirming rapid YUTREPIA commercialization
  • Q2 operating income $85.5M versus $(37.5)M prior-year loss, marking a major profitability inflection
  • Adjusted EBITDA $96.3M, up from $71.2M in Q1 2026, supporting self-funded clinical expansion
  • Ending cash $284.2M, up $61.4M sequentially, strengthening funding capacity for 10 ongoing or planned studies
  • Litigation remains the primary commercial risk: United Therapeutics seeks injunctive relief that could block YUTREPIA sales

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Liquidia Corp 8-K filings

Get the next LQDA 8-K as it lands

Follow LQDA for push alerts, or ask the research agent what this filing means.